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In order to determine the source of epidermolysis bul-
losa acquisita (EBA) antigen, we studied its synthesis by 
human keratinocytes and fibroblasts in culture. To iden-
tify the antigen, we used the sera of 5 patients with 
EBA. These sera had antibodies directed against the 
epidermal basement membrane zone (BMZ) at titers of 
5-80. The 5 sera were further characterized by immu-
noblotting on extracts of the epidermal BMZ. In concert 
with previous reports, 4 sera stained a 290 kD polypep-
tide, 3 sera weakly stained a 145 kD polypeptide, and 1 
serum did not bind either polypeptide. To study the 
synthesis of the EBA antigen, cultured human keratin-
ocytes and fibroblasts, derived from neonatal foreskins, 
were metabolically labeled with 14C-labeled amino 
acids. Radiolabeled newly synthesized proteins that 
were extracted from these cultures with nonionic deter-
gent were used in an immunoprecipitation assay. The 
precipitated proteins were identified by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and fluorog-
raphy. All 5 EBA sera, but none of 3 bullous pemphigoid 
or 4 normal human sera, precipitated a 290 kD polypep-
tide from extracts of both keratinocytes and fibroblasts. 
Approximately equal amounts of this 290 kD polypep-
tide were precipitated from equivalent amounts of ex-
tracts from either cell type. The 290 kD polypeptide 
was also specifically precipitated by EBA sera from 
extracts of a human squamous cell carcinoma line, SCC-
15. The 145 kD polypeptide was not detected in the 
newly synthesized proteins of any of these cell cultures. 
This finding suggests that the 145 kD polypeptide is not 
a precursor of the 290 kD polypeptide. Taken together 
these results demonstrate that the EBA antigen is syn-
thesized by both human keratinocytes and fibroblasts, 
and is not a tissue (epidermal)-specific product. 
Epidermolysis bullosa acquisita (EBA) is a subepidermal 
blistering disease in which antibodies develop against the epi-
dermal basement membrane zone (BMZ) [1-4). Patients usu-
ally develop blisters in areas of trauma with subsequent milia 
and scar formation, however this disease can also present as an 
inflammatory bullous disorder with the distribution and mor-
phology of the lesions very similar to that seen in bullous 
pemphigoid or cicatricial pemphigoid [5,6). Histology of the 
blister in EBA demonstrates a subepidermal vesicle with mark-
edly variable inflammation in the papillary dermis [3,5). In-
flammatory cells, if present, usually include neutrophils with 
or without eosinophils. Electron microscopic examination of 
early blisters has shown that the vesicle forms in the papillary 
dermis, just beneath the lamina densa [2,4,7). Direct immuno-
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fluorescence of perilesional skin from these patients has dem-
onstrated in vivo-bound immunoglobulin (usually IgG) and C3 
at the epidermal BMZ [1- 5,7,8) . Many of these patients also 
have serum antibodies that bind to the epidermal BMZ 
of normal skin, as shown by indirect immunofluorescence (2-
5,8]. Immunoelectron microscopy has localized the binding of 
these antibodies to a diffuse area below, and sometimes also 
within, the lamina densa, but the binding site does not corre-
spond to any particular structure in or below the BMZ 
[2,4,9,10). 
A recent study has shown that serum antibodies from EBA 
patients define a unique BMZ antigen, called EBA antigen 
[9). This antigen was identified by an immunoblotting tech-
nique. Polypeptides, extracted from the normal epidermal 
BMZ, were separated by sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE), then electrophoreti-
cally transferred to nitrocellulose paper. As identified by im-
munoperoxidase staining or [1 251]protein A autoradiography, 
antibodies in EBA sera specifically bound to a polypeptide that, 
u~der reducing _conditions, was of M, approximately 290,000. A 
mmor polypeptide of 145 kD was also detected by most of these 
sera. The EBA antigen is thus distinct from other known 
epidermal BMZ molecules such as bullous pemphigoid antigen, 
type IV collagen, and laminin. 
The above studies have defined the EBA antigen as a unique 
epidermal BMZ antigen that is found both within and just 
below the lamina densa, but not well localized to any known 
BMZ or dermal structure. The cell which synthesizes this 
antigen is basically unknown, although immunoelectron micro-
scopic studies have suggested that it might be synthesized by 
keratinocytes [4,10]. This hypothesis would be consistent with 
the finding that the EBA antigen is localized specifically in the 
BMZ of epidermis. 
In this study we directly demonstrate that human keratino-
cytes do synthesize the EBA antigen, but, perhaps surprisingly, 
so do human dermal fibroblasts . These studies suggest that the 
antigen itself is not a tissue-specitic product even though it 
may accumulate at a specific tissue localization. 
MATERIALS AND METHODS 
Sera 
Sera from 5 patients with EBA were used. (The sera from 2 of our 
patients, including the l negative by immunoblotting, were included in 
the report by Woodley et al (9] on the characterization of the EBA 
antigen.) These patients had typical clinical findings of EBA. In 
addition, these patients had both in vivo-bound and serum antibodies 
against the epidermal BMZ. Immunoelectron microscopy (4 of 5 pa-
tients) , as well as indirect immunofluorescence on 1.0 M NaCl-sepa-
rated skin on all patients (see Results), demonstrated that the antibod-
ies from these patients bound the BMZ at or just below the lamina 
densa. As controls for both immunoblotting and immunoprecipitation 
experiments, a total of sera from 5 patients with bullous pemphigoid 
were used. These sera, when tested by indirect immunofluorescence on 
normal human skin or monkey esophagus, had IgG antibodies which 
bound the epidermal BMZ at titers of greater than 160. These sera also 
bound the bullous pemphigoid antigen (an approximatel.y 230 kD 
polypeptide) , as determined by immunobotting and/or immunopreci-
pitation [11,12]. Finally, 7 normal human sera were also used as 
controls. 
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I rnmunoblotting 
To determine whether the EBA sera contained ant ibodies to t he 
EBA antigen , as defined by Woodley eta! [9], we used immunoblotting. 
The method described by Woodley et a! [9) was used with minor 
modifications. Normal skin was obta ined from an amputated leg with 
a Castroviejo electrokeratome (Storz Instrument Co., St. Louis, Mis-
souri) set at a depth of 0.5 mm. The skin was incubated in 1.0 M NaCl 
(with 1 mM PMSF and 1 mM EDTA) at 4' fo r 72 h. The epidermis was 
removed and t he top of the dermis (wh ich contains t he lamina densa) 
was extracted for 1 h at room temperature with a 0.125 M Tris-HCI, 
pH 6.8, buffer containing 2% SDS, 8 M urea, 0.1 M dithiothreitol, 1 
mM PMSF, and 2 mM EDTA. Approximately 380 11l of ext raction 
buffer was used per cm2 of dermal surface area. Extracted polypeptides 
were separated by SDS-PAGE, electrophoretically t ransferred to ni tro-
ce llulose paper, and stained with EBA sera by t he immunoperoxidase 
technique as previously described [12]. 
Cell Culture 
Human epidermal cells, obta ined from neonatal foresk ins, were 
cultured on 3T 3 cells [13,14) or on collagen substrates [15], as previ-
ous ly described. Cells grown on 3T 3 feeders were used in the second 
passage at confluence; cells grown on collagen were used as primary or 
third passage cul ture . . As previously described, when these epidermal 
cell colonies expand, the 3T 3 cells a re first pushed aside, then form 
islands of amorphous debris, and a re eventually undetectable by light 
microscopy when the epidermal cells a re con flu ent . Human fibroblasts 
were obtained by mincing the dermis, which was separated from the 
epidermis by overnight trypsinization at 4' C [15], and culturing the 
small pieces in Dulbecco's modified Eagle 's medium wi th 10% fetal 
bovine serum unt il fibroblast colonies started to grow. The pieces of 
d e rmis were then removed. Fibroblasts were allowed to grow to conflu-
ence, then passaged. Fibroblasts were used in the first passage at 
con tluence. At t his time no epit helia l colonies were visible. Finally, a 
keratinocyte cell line, SCC-15, derived fro m a human squamous cell 
carcinoma (a kind gift of Dr. James Rheinwald), was cul tured without 
a n y feeder laye r, and was used at conlluence. 
Radio/abe ling and Extraction of Cell Cultures 
To radiolabel the EBA ant igen and to demonstrate its synt hesis, we 
metabolically radiolabeled the cell cul tures with 12.5- 25 11Ci/ ml of a 
mixture of 14C-labeled amino acids (NEC-445E, New England Nuclear, 
Boston, Massachusetts) and extracted the cells with Nonidet P -40, as 
previously described [16). These radiolabeled extracts, as well as the 
radiolabeled cell culture medium, were used fo r immunoprecipi tation 
assays. 
I mrnunoprecipitation 
To identi(y the EBA ant igen that was newly synt hesized in cell 
cu l t ure, we used an immunoprecipitat ion assay which we have previ-
ous ly desc ribed in detai l [17] . In brief, for each immunoprecipi tation 
approximately 4 x 10" cpm of radioactive protein was preabsorbed with 
20 p.] of normal human serum and 400 11l of a 10% suspension of protein 
A -bearing staphylococci (Pansorbin , Calbiochem-Behring Corp. , San 
Diego, California). The preabsorbed radiolabeled cell extract or medium 
was t hen incubated with 10 11! of EBA or control serum. Antigen-
antibody complexes were precipitated with 100 11! of a 10% suspension 
of protein A-bea ring staphylococci. The immunoprecipi tates were sol-
ubilized in 2% SDS, 0.1 M dithiothreitol in 0.125 M Tris-HCl, pH 6.8, 
buffer, separated by SDS-PAG E, and the radiolabeled precipitated 
po lypeptides were identi!ied by !luorography. 
In all immunoprecipitations shown in t his paper, identical amounts 
of protein-incorporated radioactivity (approximately 4 X 106 cpm) were 
u sed. Thus, ident ical amounts of protein were used in comparing 
normal human keratinocytes, SCC-15, and normal human tibroblasts. 
RESULTS 
Characterization of EBA S era by lmmunofluorescence and 
I rnrnunoblottin.g 
Our EBA sera were titered by indirect immunofluorescence 
against 1.0 M N aCI-split uormal huma n skin , as described by 
Gammon et a ! [18] . As expected fo r EBA sera [18 ], all sera 
bound to the base, at titers of 5- 80 (Table I) . 
Woodley et a l [9] have defi ned t h e EBA an t igen by immu-
noblotting performed on extracts of the BMZ of normal huma n 
s kin. By t his method, a ll but one of their sera bound a 290 kD 
TABLE I. Characterization of EBA sera by indirect 
immunofluorescence and immu.noblotting 
Patient number 
523 
525 
536 
542 
620 
Indirect 
immunofluorescence 
40 
80 
20 
10 
5-80d 
Molecular weight of 
bands identified by 
imrnunoblotting 
(kD)• 
290,145 
290,145 
290,145 
290 
a Performed on 1.0 M NaCl-split skin as described by Gammon et al 
(18]. All se ra stained the basement membrane zone on t he base (dermal 
side), as previously described [18). 
b Molecular weights, as estimated by SDS-PAGE, were approxi-
mately t hose determined by Woodley et al [9], and are therefore 
assigned t he same values as previously reported. 
c No bands were identified. 
d Several sera with different ti ters were obtained from this patient. 
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FIG 1. Identification of EBA ant igen by immunoblotting. Epidermal 
BMZ was extracted with 8 M urea, 2% SDS, and 0.1 M dithiothreitol. 
The extracted polypeptides were separated by SDS-PAGE, then elec-
tror-horetically t ransferred to ni trocellulose. Immunoper0xidase stain-
ing was performed on identical lanes of protein as follows: lane l -
EBA serum #542; lane 2-EBA serum #536; lane 3-bullous pemphigoid 
serum #51; lane 4-normal human serum #84. The arrow indicates the 
290 kD major polypeptide of EBA antigen. The arrowhead indicates 
the minor 145 kD band. (Migration of concurrently run standards is 
shown at right, kD X 10-3 . ) 
polypeptide and most sera a lso bound a minor component at 
145 kD. We tested our sera by immunoblotting (Fig 1, Table 
I). Epidermis was rem oved from normal human skin after 
incubation in 1.0 M NaCl at 4oC for 72 h . The top ofthe dermis 
(which contains the lamina densa) was extracted with 2% SDS, 
8 M urea, a nd 0.1 M dithiothreitol. The extracted polypeptides 
were sepa rated by SDS-PAGE a nd t hen electrophoretically 
t ra nsferred to nitrocellulose paper. Immunoperoxidase staining 
of the t ransferred polypeptides was performed with EBA sera 
or, as con t rols, normal human sera or bullous pemphigoid sera. 
The typical staining of t he 290 kD and t h e minor 145 kD bands 
was seen with 3 of our 5 EBA sera (Table I; Fig 1 shows t h e 
typica l staining pattern). The molecular weigh ts are approxi-
mate, as determined by concurrent ly run standards. Our cal-
culations of t he Mr of t he bands was sligh t ly lower t han reported 
by Woodley et a ! [9], but since these Mr are rough estimates 
anyway (especially the 290 kD determination because it is 
extrapolated beyond t h e highest standard of 200 kD ) we have 
chosen to label the Mr the same as Woodley et a! to prevent 
confusion. One of our sera stained only t h e 290 kD polypeptide 
and one did not bind any band in the BMZ extract (Table 1). 
Five norma l human sera a nd 4 bullous pemphigoid sera did not 
bind the 290 kD or 145 kD polypeptides. 
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Immunoprecipitation of EBA Antigen from Radiolabeled 
Extracts of Human Keratinocytes and Human Fibroblasts 
Proteins synt hesized by cultured human keratinocytes and 
fibroblasts, obtained from neonatal foreskin, were radiolabeled 
with •·•c amino acids. Radiolabeled newly synthesized polypep-
tides were extracted from the cell layer with non ionic detergent. 
EBA sera were incubated with aliquots of these extracts t hat 
contained equa l amounts of protein-incorporated radioactivity. 
All 5 EBA sera, including the 1 (#523) negative by immuno-
blotting, precipitated a 290 kD polypeptide from both fibroblast 
and keratinocyte extracts (Fig 2). The intensity of t he 290 kD 
band as visualized by fluorography was about equal when 
precipitated from equal amounts of radioactive protein from 
either extract. Three bullous pemphigoid sera and 4 normal 
human sera, used as controls, did not precipitate these bands. 
However, bullous pemphigoid sera did precipitate the bullous 
pemphigoid a ntigen, a 230 kD polypeptide, from keratinocyte 
but not from fibroblast extracts (Fig 2b). These data indicate 
that EBA ant igen is synthesized by both keratinocytes and 
fibroblasts in culture. Even the one serum that did not bind 
t he 290 kD band by immunoblotting, did bind this polypeptide 
in the immunoprecipitation assay. The minor 145 kD polypep-
tide was not detected in t hese immunoprecipitation experi-
ments. 
Immunoprecipitation of t he cell culture medium of the fibro-
blasts demonstrated barely detectable amounts of the 290 kD 
polypeptide, which indicates t hat most of t he EBA antigen is 
found in the cell layer, but that small amounts may leak from 
the cells into t he medium. 
The EBA antigen detected by immunoprecipitation from 
both fibroblast and keratinocyte extracts is unlikely to be due 
to a small population of contaminating cells. If the precipitated 
antigen from one cell type was solely due to a small contami-
nating population of the other cell type, the amount of antigen 
precipitated, and hence the intensity of the radioactive band as 
1 23456 1 2 3456 78910 
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FIG 2. lmmunoprecipi tation of EBA antigen from the newly syn-
thesized proteins of cultured human fibroblasts and keratinocytes. 
Confluent cultures of human fibroblasts and keratinocytes were incu-
bated with "C-Iabeled amino acids. The cultures were then extracted 
with nonionic detergent, and the extracted labeled proteins were im-
munoprecipitated with various sera. lmmunoprecipi tated protein was 
identified by SDS-PAGE and fluorography. a, Lanes 1-3 are immune-
precipitates of fibroblast extracts; lanes 4-6 are of keratinocyte extracts. 
The following sera were used: lanes I and 4- EBA #525; lanes 2 and 
5-EBA #536; lanes 3 and 6- normal human sera #4 71. b, Lanes 1-5 
are immunoprecipitates of fibroblast extracts; lanes 6-10 are of kera-
tinocyte extracts. The following sera were used: lanes 1 and 6-EBA 
#523; lanes 2 and 7-EBA #542; lanes 3 and 8-EBA #620; lanes 4 and 
9-bullous pemphigoid 1/50; lanes 5 and /0-normal human serum 
f/60 1. A rrows indicate 290 kD band of EBA antigen. Arrowhead indi -
cates 230 kD band of bullous pemphigoid antigen. The low M, band in 
lane 9 may represent a breakdown product of bullous pemphigoid 
antigen; it is not precipitated by other bullous pemphigoid sera. (Mi-
gration of standards, kD X 10-3, is shown at right.) 
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seen by f1uorography, would be markedly diminished in the 
contaminated population. This was not the case because im-
munoprecipitates of keratinocyte and fibroblast extracts gave 
approximately equal intensity bands. In addition, examination 
by phase cont rast microscopy of confluent primary fibroblast 
culture did not reveal any epithelial cells. To further eliminate 
the possibility of minor keratinocyte contamination, fibroblasts 
were passaged and grown to confluence again before radiola-
beling. Finally, the absence of bullous antigen in immunopre-
cipitates of fibroblast extracts demonstrates that there is no 
significant keratinocyte contamination. Conversely, in keratin-
ocyte cultures, neither 3T3 cells nor fibroblasts were visible at 
confluence. To further eliminate the possibility of contaminat-
ing fibroblasts or 3T3 cells, a human squamous cell carcinoma 
cell line (SCC-15) was used. This cell line has been cultured 
through many passages without a feeder layer or fibroblasts. 
This cell line also synthesized the EBA antigen (Fig 3). Finally, 
human epidermal cells cultured on collagen gels without a 
feeder layer [15] also synthesized EBA antigen (data not 
shown). 
DISCUSSION 
Woodley et al (9] have recently demonstrated, by immuno-
blotting of normal epidermal BMZ extracts, that almost all 
EBA sera stain a major polypeptide band of 290 kD and most 
EBA sera stain a minor band at 145 kD. We obtained similar 
results when our sera were tested by immunoblotting: 4 of 5 
stained the 290 kD polypeptide, 3 also stained faintly a 145 kD 
polypeptide. One EBA serum did not stain any bands by 
immunoblotting. In contrast to the immunoblotting results, by 
immunoprecipitation of radiolabeled extracts of human fibro-
blasts and keratinocytes, all 5 sera, including the 1 that was 
negative by immunoblotting, precipitated a 290 kD polypeptide 
and none reacted with a 145 kD polypeptide. 
These results indicate that both cultured human keratino-
cytes and human fibroblasts synthesize EBA antigen. This 
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FIG 3. EBA antigen is synthesized by a human squamous cell car-
cinoma cell line, SCC-15. Radiolabeling of cells and immunoprecipita· 
tion were performed as described in Fig 2. Lanes 1-5 are immunopre-
cipitates of the SCC-15 radiolabeled extract and lanes 6 and 7 are of 
the human fibroblast extract. The following sera were used: lanes I and 
6-EBA #525; lane 2-EBA #536; lane 3-bullous pemphigoid #50; 
lane 4-normal human serum #407; lanes 5 and 7-normal human 
serum #538. Arrow indicates the 290 kD band of EBA antigen. A rrow-
head indicates the bu llous pemphigoid antigen, which in this case is 
seen as a doublet, as has been previously reported (12] . The other 
bands that are seen in lane 3 probably represent breakdown products 
of bullous pemphigoid antigen, which are seen much more in extracts 
of this transformed cell line than in extracts of cultures of normal 
human keratinocytes. (Migration of standards, kD x 10-3, is shown at 
right.) 
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conclusion implies that EBA antigen is not a tissue-specific 
product. This finding, along with the fact t hat, on the ultra-
structural level, EBA antigen is not associated with any partic-
ular structure, may suggest, but does not prove, that EBA 
antigen is not a specific structural component of the epidermal 
BMZ but may be a cell product, produced by different types of 
cells, that happens to become trapped near the epidermal BMZ. 
The reason EBA antibodies do not precipitate a 145 kD 
polypeptide from the newly synthesized proteins of fibroblasts 
and keratinocytes is not clear, but there are several possible 
explanations. It is possible t hat the 145 kD polypeptide is a 
breakdown product of the 290 kD polypeptide, which occurs 
only in the immunoblotting studies because of the long (72-h) 
incubation of sk in in 1.0 M NaCI. On the other hand, the 145 
kD polypeptide may be a specific metabolic product of the 290 
kD protein, which occurs only in vivo, not in vitro. It is unlikely 
that the 145 kD polypeptide is a precursor of the 290 kD 
polypeptide, because the same precursor would be expected to 
be present in the newly synthesized proteins of cultured cells. 
Finally, it is interesting that one EBA serum bound the 290 
kD polypeptide in immunoprecipitation but not immunoblot-
ting studies. This is most likely explained by the fact that in 
immunoblotting experiments the proteins used for antibody 
staining are denatured (due to preparation for SDS-PAGE) 
whereas in immunoprecipitation experiments the proteins are 
only extracted with nonionic detergent (non-denaturing con-
ditions) before incubation with antibodies. These differences 
in technique suggest that at least some EBA sera have antibod-
ies which bind only to non-denatured antigen. 
Further studies will be needed to clarify the biologic function 
of t he EBA antigen. However, it is clear from the studies 
presented here that in most, if not a ll, patients with EBA a nd 
circulating autoantibodies, these antibodies define a unique 
molecule which is synthesized by both keratinocytes and fibro-
blasts. 
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